Verily, Alphabet Inc.’s (NASDAQ: GOOGL) life sciences research organization, announced that it will be forming a new joint venture with ResMed (NYSE: RMD), a global leader in sleep apnea treatment and connected health solutions. Sleep apnea, a serious sleep disorder in which breathing repeatedly stops and starts during sleep, affects roughly 54 Million people in the U.S., with past research indicating that approximately 80% of obstructive sleep apnea go undiagnosed and untreated.
The joint venture will be based in the U.S., focusing on health and financial impacts of undiagnosed and untreated sleep apnea, and developing software solutions that will enable healthcare providers to more accurately and efficiently identify, diagnose, treat, and manage individuals with sleep apnea and other breathing related sleep disorders.
Sleep apnea has been associated with heart disease, stroke, type 2 diabetes, and other life-threatening conditions. Due to most individuals being unaware that they have sleep apnea, they are unaware of the risk they are in and the benefits that therapy could provide them. People affected by sleep apnea often wake up feeling tired despite a full night of sleep, have loud snoring, and interrupted breathing at night.
“The vast majority of people with sleep apnea don’t realize they have it, and therefore don’t seek accessible, effective treatment to mitigate its effects and long-term health risks,” said ResMed Chief Medical Officer Carlos M. Nunez, M.D. “The combined industry expertise, scalable infrastructure, and data analytics capabilities of ResMed and Verily can unlock meaningful ways to identify these individuals and support their journey to improved sleep, health and quality of life.”
The joint venture is expected to operate independently, as a separate venture from ResMed and Verily.